Skip to main content
OpenTrials
Completed

NCT Number: NCT02652065

Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis

Psoriasis is a chronic inflammatory cutaneous disease, affecting 3% of the French population. Among psoriatic patients, 80% feel pain or cutaneous discomfort related to their pathology.

Neurogenic inflammation's role in psoriasis has recently been put forward by a study showing that TRPV1 ion channels are necessary to establish psoriasiform inflammation in mice.

The investigators hypothesize that there is a link between cutaneous sensory neuropathies and altered cutaneous microcirculation during psoriasis.

In order to test this hypothesis, local vasodilators will be delivered to patients by iontophoresis and their skin blood flow in response to these molecules will be followed by laser Doppler recordings. Two recordings will be performed for each patient, both on a psoriasis plaque and on uninvolved skin, in order for the patient to be his own internal control.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

20 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Edouard Herriot - Service de Dermatologie et Vénéréologie

Lyon, 69437, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type I psoriasis
  • Psoriasis plaques on the patient's back

Exclusion criteria

  • BMI > 25
  • Diabetic patient
  • Arteriovenous disease history
  • Ongoing anti-inflammatory treatment
  • Major cardiovascular history (<3 months)
  • Hypertension
  • Topical treatment on the back skin (<7 days)
  • Systemic treatment (steroids, methotrexate, retinoids, cyclosporine) or phototherapy (<1 month)
  • Pregnant women
  • Subject within exclusion period following a previous or ongoing biomedical study

Treatment and study plan

Acetylcholine iontophoresis

Other

Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).

Sodium Nitroprussiate iontophoresis

Other

Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).

ppi water iontophoresis

Other

ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).

Laser Doppler recording

Other

Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.

Primary outcomes

  1. skin blood flow variation

    Time frame: at the latest 3 months after inclusion

    Skin blood flow variation on healthy skin and on psoriasis plaque will be measured by Laser Doppler in response to iontophoretic delivery of vasodilator substances (sodium nitroprussiate and acetylcholine) and ppi water. Skin blood flow will be recorded during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.

Secondary outcomes

  1. Sensory detection threshold

    Time frame: at the latest 3 months after inclusion

    Increasing size of Von Frey filaments will be placed onto patients' skin to assess sensory detection threshold.

  2. Potential discomfort sensation thresholds

    Time frame: at the latest 3 months after inclusion

    Increasing size of Von Frey filaments will be placed onto patients' skin to assess potential discomfort sensation threshold.

  3. Heat sensitivity

    Time frame: at the latest 3 months after inclusion

    Heat sensitivity will be assessed using hot (50°C) and cold (4°C) water

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: MicroPso

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Jan 11, 2016
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.